New hope for endometrial cancer: phase 3 trial launches for targeted drug
NCT ID NCT07286331
First seen Jan 10, 2026 · Last updated Jun 19, 2026 · Updated 30 times
Summary
This phase 3 trial will test a new drug called mocertatug rezetecan against standard chemotherapy in 600 people with endometrial cancer that has progressed after platinum-based chemo and immunotherapy. The goal is to see if the new drug shrinks tumors or delays cancer growth better than current options. Researchers will also monitor safety and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS, ENDOMETRIAL are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mocertatug rezetecan (a targeted drug)
What this could lead to
If it works, this could offer a new treatment option for endometrial cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-stage comparison; the new drug may not work better than chemotherapy and could have unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.